Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Gluten-free diet remains a strong treatment option for dermatitis herpetiformis

29 Sep 2019

Majority of patients with dermatitis herpetiformis (DH) are unable to regain gluten tolerance, a recent study has shown. A lifelong gluten-free diet (GFD) therefore remains warranted as a treatment option.

Researchers performed a gluten challenge on 19 DH patients (mean age, 58 years; 13 males) who had been adhering to a GFD for a mean of 23 years. The challenge involved daily consumption of 200 g of commercially available wheat bread for 3 days. Skin and small-bowel biopsies were obtained before and after the gluten challenge to assess DH and/or coeliac disease manifestations.

After the gluten challenge, 15 patients experienced rashes over a mean of 5.6 months, corresponding to an incidence rate of 79 percent. At postchallenge, 12 showed small-bowel mucosal atrophy and 10 had serum samples enriched with antibodies targeting transgutaminase (TG) 2.

Moreover, two patients who had no rashes developed high levels of immunoglobulin (Ig) A-class TG-2 targeted antibodies and had to discontinue the gluten challenge at 4 months. One other patient with no rashes showed villous atrophy upon small bowel biopsy at 12 months. Therefore, a total of 18 patients experienced relapse, with an overall rate of 95 percent.

Only one patient did not relapse, showing normal skin and gastrointestinal symptoms throughout the challenge period, as well as having normal biopsy findings. As expected, the prechallenge biopsies did not exhibit rashes nor IgA and TG3 deposits.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
5 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
6 days ago
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.